LON:SLN - Silence Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 152.25 -1.25 (-0.81 %)
(As of 05/23/2018 04:00 PM ET)
Previous CloseGBX 152.25
Today's RangeGBX 150 - GBX 151
52-Week RangeGBX 71.88 - GBX 254.75
Volume14,386 shs
Average Volume13,380 shs
Market Capitalization£136.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Silence Therapeutics (LON:SLN)

Silence Therapeutics logoSilence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SLN
CUSIPN/A
Phone+44-20-34576900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-34,475.00%
Return on Equity-21.42%
Return on Assets-20.54%

Miscellaneous

EmployeesN/A
Outstanding Shares69,990,000

Silence Therapeutics (LON:SLN) Frequently Asked Questions

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics (LON:SLN) announced its quarterly earnings data on Tuesday, March, 6th. The company reported ($2.30) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter. Silence Therapeutics had a negative net margin of 34,475.00% and a negative return on equity of 21.42%. View Silence Therapeutics' Earnings History.

What price target have analysts set for SLN?

1 brokers have issued 12-month price objectives for Silence Therapeutics' shares. Their forecasts range from GBX 277 to GBX 277. On average, they anticipate Silence Therapeutics' stock price to reach GBX 277 in the next year. View Analyst Ratings for Silence Therapeutics.

Who are some of Silence Therapeutics' key competitors?

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the folowing people:
  • Mr. Ali Mortazavi, Chief Exec. Officer and Director (Age 47)
  • Mr. David J. Ellam, Chief Financial Officer, Sec. and Director (Age 54)
  • Dr. Torsten Hoffmann, Chief Operating Officer (Age 51)
  • Dr. Dmitry Samarsky Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Mark Cameron, Head of Chemistry

Has Silence Therapeutics been receiving favorable news coverage?

Headlines about SLN stock have been trending positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Silence Therapeutics earned a news impact score of 0.40 on Accern's scale. They also gave press coverage about the company an impact score of 47.09 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Silence Therapeutics?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 152.25.

How big of a company is Silence Therapeutics?

Silence Therapeutics has a market capitalization of £136.14 million.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.


MarketBeat Community Rating for Silence Therapeutics (SLN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Silence Therapeutics (LON:SLN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Silence Therapeutics in the last 12 months. Their average twelve-month price target is GBX 277The high price target for SLN is GBX 277 and the low price target for SLN is GBX 277. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 277GBX 277GBX 275GBX 249

Silence Therapeutics (LON:SLN) Consensus Price Target History

Price Target History for Silence Therapeutics (LON:SLN)

Silence Therapeutics (LON:SLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/3/2018Peel HuntReiterated RatingBuyGBX 277View Rating Details
1/9/2017Canaccord GenuityReiterated RatingBuyGBX 249View Rating Details
(Data available from 5/23/2016 forward)

Earnings

Silence Therapeutics (LON:SLN) Earnings History and Estimates Chart

Earnings by Quarter for Silence Therapeutics (LON:SLN)

Silence Therapeutics (LON SLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018Y 2017GBX (2.30)GBX 2 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Silence Therapeutics (LON:SLN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Silence Therapeutics (LON SLN) Insider Trading and Institutional Ownership History

Insider Trading History for Silence Therapeutics (LON:SLN)

Silence Therapeutics (LON SLN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2017Alistair GrayInsiderBuy3,848GBX 130£5,002.40
7/31/2017Andy RichardsInsiderBuy7,000GBX 147£10,290
4/18/2016Mortazavi,AliInsiderBuy160,000GBX 125£200,000
(Data available from 1/1/2013 forward)

Headlines

Silence Therapeutics (LON SLN) News Headlines

Source:
DateHeadline
Silence Therapeutics (SLN) Earns Buy Rating from Peel HuntSilence Therapeutics (SLN) Earns Buy Rating from Peel Hunt
www.americanbankingnews.com - April 3 at 9:17 AM
Silence Therapeutics (SLN) Receives Buy Rating from Peel HuntSilence Therapeutics (SLN) Receives Buy Rating from Peel Hunt
www.americanbankingnews.com - March 30 at 1:48 PM
Silence Therapeutics (SLN) "Buy" Rating Reiterated at Peel HuntSilence Therapeutics' (SLN) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 27 at 12:34 PM
Silence Therapeutics (SLN) Stock Rating Reaffirmed by Peel HuntSilence Therapeutics (SLN) Stock Rating Reaffirmed by Peel Hunt
www.americanbankingnews.com - March 26 at 9:54 AM
Silence Therapeutics (SLN) Receives "Buy" Rating from Peel HuntSilence Therapeutics (SLN) Receives "Buy" Rating from Peel Hunt
www.americanbankingnews.com - March 26 at 12:04 AM
Peel Hunt Boosts Silence Therapeutics (SLN) Price Target to GBX 277Peel Hunt Boosts Silence Therapeutics (SLN) Price Target to GBX 277
www.americanbankingnews.com - March 6 at 10:30 AM
Silence Therapeutics (SLN) Posts Quarterly  Earnings ResultsSilence Therapeutics (SLN) Posts Quarterly Earnings Results
www.americanbankingnews.com - March 6 at 8:24 AM
What’s The Market Sentiment Around Loss-Making Silence Therapeutics plc (LON:SLN)?What’s The Market Sentiment Around Loss-Making Silence Therapeutics plc (LON:SLN)?
finance.yahoo.com - March 1 at 4:12 PM
Silence Therapeutics (SLN) Rating Reiterated by Peel HuntSilence Therapeutics (SLN) Rating Reiterated by Peel Hunt
www.americanbankingnews.com - December 28 at 6:16 AM
Silence Therapeutics (SLN) Now Covered by Peel HuntSilence Therapeutics (SLN) Now Covered by Peel Hunt
www.americanbankingnews.com - December 16 at 9:22 PM
Should You Be Concerned About Silence Therapeutics plc’s (AIM:SLN) -27.5% Earnings Decline?Should You Be Concerned About Silence Therapeutics plc’s (AIM:SLN) -27.5% Earnings Decline?
finance.yahoo.com - December 4 at 11:19 AM
Silence Therapeutics Plc – Value Analysis (LONDON:SLN) : November 21, 2017Silence Therapeutics Plc – Value Analysis (LONDON:SLN) : November 21, 2017
finance.yahoo.com - November 22 at 8:06 AM
Silence Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SLN-GB : November 20, 2017Silence Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SLN-GB : November 20, 2017
finance.yahoo.com - November 20 at 10:01 AM
What You Must Know About Silence Therapeutics plc’s (AIM:SLN) RisksWhat You Must Know About Silence Therapeutics plc’s (AIM:SLN) Risks
finance.yahoo.com - September 23 at 7:00 AM
Silence Therapeutics plc (SLN) Insider Alistair Gray Purchases 3,848 SharesSilence Therapeutics plc (SLN) Insider Alistair Gray Purchases 3,848 Shares
www.americanbankingnews.com - August 3 at 4:32 AM
Silence Therapeutics plc (LON:SLN) Insider Andy Richards Purchases 7,000 SharesSilence Therapeutics plc (LON:SLN) Insider Andy Richards Purchases 7,000 Shares
www.americanbankingnews.com - July 31 at 7:16 AM
Silence Ther. Share ChatSilence Ther. Share Chat
www.lse.co.uk - July 28 at 7:59 AM
Full Year 2016 Silence Therapeutics PLC Earnings Release - Before Market OpenFull Year 2016 Silence Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - March 28 at 9:19 AM
[$$] Elliott Associates Sees Potential in Advisory Board Co. Sale[$$] Elliott Associates Sees Potential in Advisory Board Co. Sale
www.barrons.com - January 21 at 1:22 AM
[$$] DNA editing accelerates along controversial healthcare path[$$] DNA editing accelerates along controversial healthcare path
www.ft.com - November 29 at 3:25 PM
[$$] DNA editing accelerates along controversial healthcare path[$$] DNA editing accelerates along controversial healthcare path
www.ft.com - November 29 at 3:25 PM
Half Year 2016 Silence Therapeutics PLC Earnings Release - Before Market OpenHalf Year 2016 Silence Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - September 27 at 11:57 AM
Should You Dump AstraZeneca plc And Buy BTG plc & Silence Therapeutics plc?Should You Dump AstraZeneca plc And Buy BTG plc & Silence Therapeutics plc?
uk.finance.yahoo.com - April 5 at 11:24 AM

SEC Filings

Silence Therapeutics (LON:SLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Silence Therapeutics (LON SLN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.